Sign in
Active, not recruitingPhase 3

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Key facts

Who runs it
Ionis Pharmaceuticals, Inc.
Where
Ann Arbor, Baltimore, Boca Raton, Bossier City, Boston, Brooklyn, Carmel, Charleston, Charlotte, Chattanooga, Columbus, Dallas, Edmond, Flint, Greenacres City, Greensboro, Houston, Jackson, Kansas City, Kerrville, Lampasas, Las Vegas, Lenoir, Lexington, Lincoln, Little River, Los Angeles, Louisville, Manassas, McAllen, McKinney, Mesquite, Miami, Mineola, Miramar, Morgantown, New York, Norfolk, North Miami Beach, Oak Brook, Odessa, Orchard Park, Philadelphia, Rapid City, San Antonio, San Diego, St Louis, Tampa, Tarzana, Towson, Trinity, Tulsa, Union City, Webster, and Winston-Salem, United StatesSee the 65 sitesAlso in 32 other countries, 201 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
885 people enrolled
Started
13 Dec 2022
Expected to end
Mar 2027
Type of study
Interventional
Treatments tested
  • Olezarsen
Record updated
1 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Satisfactory completion of either ISIS 678354-CS5 or ISIS 678354-CS6 with an acceptable safety profile, per Investigator judgment. Satisfactory completion requires that the patient did not terminate early from treatment
  • Participants must be on a stable regimen of lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. A patient may be eligible if their regimen of lipid-lowering therapy has been changed recently, provided that lipid lowering medications are optimized and stabilized for at least 4 weeks prior to the end of the Qualification Period of this OLE study; ideally, such changes are initiated after Week 53 of the index study (ISIS 678354-CS5 or CS6)
  • A patient may re-enroll in the study after having completed the study when the Treatment Period was 53 weeks, if the patient satisfactorily completed the study with an acceptable safety profile, per Investigator judgment. In the case of re-enrollment, there is no limit on the time gap between completion of treatment under the previous protocol and dosing upon re-enrollment (i.e., may exceed 17 weeks between doses)

Who cannot take part

  • Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study, including need for treatment with disallowed medications, or need to change the required stable regimen as per either ISIS 678354-CS5 or ISIS 678354-CS6 study entry criteria. It is acceptable to adjust a regimen of lipid-lowering therapy as described in the second Key Inclusion Criterion above, and it is acceptable to adjust or stop lipid-lowering therapy at or after Week 13 per Investigator judgment; NOTE: Other Inclusion/Exclusion criteria may apply

Where in United States

Also in 32 other countries, 201 sites

  • University of Michigan- Endocrinology & MetabolismAnn Arbor, United States
  • University of Maryland School of MedicineBaltimore, United States
  • Excel Medical Clinical TrialsBoca Raton, United States
  • Grace Research LLCBossier City, United States
  • Massachusetts General Hospital Heart CenterBoston, United States
  • Modern MedicalBrooklyn, United States
  • St. Vincent Medical Group, Inc.Carmel, United States
  • Medical University of South CarolinaCharleston, United States
  • The Presbyterian Hospital DBA Novant Health Heart and Vascular InstituteCharlotte, United States
  • Chattanooga Research & Medicine, PLLCChattanooga, United States
  • Centricity ResearchColumbus, United States
  • IACT HealthColumbus, United States
  • The Ohio State UniversityColumbus, United States
  • University of Texas, SouthwesternDallas, United States
  • Central Oklahoma Early Detection CenterEdmond, United States
  • Aa Mrc LlcFlint, United States
  • Finlay Medical ResearchGreenacres City, United States
  • Kenneth HiltyGreensboro, United States
  • Baylor College of MedicineHouston, United States
  • Juno ResearchHouston, United States
  • Pioneer Research SolutionsHouston, United States
  • The Jackson ClinicJackson, United States
  • University of Kansas Medical Center (KUMC)Kansas City, United States
  • Sante Clinical Research LLCKerrville, United States
  • FMC ScienceLampasas, United States
  • Palm Research Center IncLas Vegas, United States
  • Clinical Trials Of America LLCLenoir, United States
  • The Research Group of Lexington LLCLexington, United States
  • Bryan Medical CenterLincoln, United States
  • Walker Family CareLittle River, United States
  • LA Universal Research Center, Inc.Los Angeles, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)Louisville, United States
  • Manassas Clinical ResearchManassas, United States
  • DCT- McAllen Primary Care, LLCMcAllen, United States
  • Texas Institute of CardiologyMcKinney, United States
  • SMS Clinical Research, LLCMesquite, United States
  • Southern Endocrinology AssociatesMesquite, United States
  • Columbus Clinical Services LLCMiami, United States
  • Finlay Medical ResearchMiami, United States
  • NYU Langone HealthMineola, United States
  • Innovia Research Center, Inc.Miramar, United States
  • WVU Heart and Vascular InstituteMorgantown, United States
  • Langone Medical CenterNew York, United States
  • Vagelos College of Physicians and Surgeons of Columbia UniversityNew York, United States
  • York Clinical ResearchNorfolk, United States
  • Harmony Clinical Research IncNorth Miami Beach, United States
  • Affinity HealthOak Brook, United States
  • Permian Research FoundationOdessa, United States
  • Orchard Park Family PracticeOrchard Park, United States
  • University of PennsylvaniaPhiladelphia, United States
  • Health ConceptsRapid City, United States
  • Monument Health Clinical ResearchRapid City, United States
  • Diabetes & Glandular Disease Clinic, P.A.San Antonio, United States
  • University of California, San Diego (UCSD)San Diego, United States
  • Washington School of MedicineSt Louis, United States
  • JSV Clinical Research Study IncTampa, United States
  • R & B Medical Center LLCTampa, United States
  • Vicis Clinical ResearchTampa, United States
  • Metabolic Institute of AmericaTarzana, United States
  • IRC ClinicsTowson, United States
  • Bayside Clinical ResearchTrinity, United States
  • Oklahoma Heart InstituteTulsa, United States
  • Hudson County Clinical Trials Research CenterUnion City, United States
  • Tranquil Clinical and Research Consulting ServicesWebster, United States
  • LexingtonWinston-Salem, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

The group in the trial

  • OlezarsenTreatment being tested

    Participants who completed either ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326) study would be enrolled to receive olezarsen, subcutaneous (SC) injection, once every 4 weeks from Week 1 through Week 153.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)
Record updated
1 December 2025